SAREUM HOLDINGS PLC

("Sareum" or the "Company")

Results of AGM

Cambridge, UK, 16 December 2021 - Sareum Holdings plc (AIM: SAR),  a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer , held its Annual General Meeting ("AGM") today and all resolutions were duly passed. Details of the voting results are shown in the table below. 

Ordinary Resolutions

Votes For

%

Votes Against

%

Votes Total

% of ISC Voted

Votes Withheld

1. Receive and adopt Report of the Directors and financial statements for the year

6,255,275

99.82

11,023

0.18

6,270,831

9.21

4,533

2. Receive and adopt Renumeration Committee report for the year

5,232,943

85.28

902,951

14.72

6,270,831

9.21

134,937

3. Re-elect Dr John Reader as Director of the Company

6,085,556

98.87

69,338

1.13

6,270,831

9.21

115,937

4. Appoint Shipleys LLP as auditor

5,618,405

91.55

518,753

8.45

6,270,831

9.21

133,673

5. Directors' authority to allot new shares

5,345,322

86.08

864,630

13.92

6,270,831

9.21

60,879

Special Resolution

 

 

 

 

 

 

 

6. Directors' authority to allot equity securities for cash

5,316,094

85.61

893,858

14.39

6,270,831

9.21

60,879

The full text of each of the resolutions is set out in the Notice of AGM, available in the Investors section of the Company's website (www.sareum.com/investors)

- Ends -

For further information, please contact: 

Sareum Holdings plc

Tim Mitchell, CEO / Alex Harrison, Investor Relations

 

 

01223 497700

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

 

 

020 7409 3494

Peel Hunt LLP (Joint Corporate Broker)

James Steel / Oliver Duckworth

 

 

020 7418 8900

Hybridan LLP (Joint Corporate Broker)

Claire Noyce

 

 

020 3764 2341

Consilium Strategic Communications (Financial PR)

Jessica Hodgson / Davide Salvi / Stella Lempidaki

 

0203 709 5700

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is focused on advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors into clinical development as potential new therapies for autoimmune diseases (with an initial focus on psoriasis), respiratory symptoms arising from viral infections and cancer immunotherapy. Sareum is also eligible to receive certain milestone payments and future royalties on SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. SRA737 was licensed to Sierra Oncology, which was acquired by GSK in June 2022.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company’s website at www.sareum.com